Augmentive.io: Transforming Access to Mental Healthcare

Augmentive is a recent addition to the portfolio and a great example of the Cambridge Angels' engagement with technology-enabled healthcare businesses. Augmentive has built an intelligent mental health system that combines its own regulated clinical service with a wider network of therapists, coaches and psychologists, all delivered through a full-stack digital health platform. Currently operating in the private market, the company is preparing to begin supporting NHS referrals. This was a recent interview with Kit Norman, co-founder and CEO.

Can you tell us a bit about your background and Augmentive?

"Pre-COVID, my brother Archie and I were running an AI lab together," Norman explains. "Archie's the data scientist, deeply technical, and I'm a product manager by background, so he'd lead on the machine learning and I'd work on turning it into something people could actually use. We had a real mix of clients, including some government organisations, and by then it was pretty clear AI was going to reshape a lot of sectors. At the same time, a few friends were really struggling to manage their mental health, and I kept coming back to the same question: why isn't anyone applying automation and machine learning here?"

The problem was, and still is, acute. Some friends were trying to find help and failing; others weren't even trying because they were so lost. Norman also knew the sector from the other side. Their mother Sarah is a therapist, and he'd seen the realities of the system up close. Sarah is also a co-founder of Augmentive, bringing her years of therapeutic experience to the business. "It was still so paper-based, fragmented and difficult to navigate," he says.

The turning point came when a childhood friend took her own life. Norman decided then that this was the problem he wanted to dedicate a large part of his life to: how do you apply what's working elsewhere to help people get the right support at the right time?

Augmentive was the result: a mental health system built from the ground up, combining a full-stack digital health platform with a regulated service designed to deliver end-to-end care pathways. In practice, that means assessment, diagnosis, treatment and aftercare, all handled out in the community through a single, managed platform. Augmentive's current focus is the UK's neurodivergent population, a group the company has identified as severely underserved. Today it has a diverse community of over 1,000 approved care providers, a specialist team of 20 consultant psychiatrists, has supported over 3,500 patients and delivered more than 25,000 hours of care. Care quality and user experience have kept pace with growth. The company's Trustpilot score is currently twice the industry average.

What are your goals for the company over the next two years?

Norman is clear about what's next. "We've been focused on the private market to date, which has been hugely valuable. It's helped us hone the product and service, and establish what good care actually looks like. But private pay will only ever reach a fraction of the people who need support. The NHS is where we feel the real impact is so the key goal is to build out that channel mix."

Augmentive has been laying the groundwork for this on several fronts. Those conversations are now at a sensitive stage, but Norman is clear about where things are headed. "We're at a critical moment. I can't say too much publicly yet, but we expect to start supporting NHS referrals in the coming months. It's an inflection point we've been building towards for many months, and being able to offer this care at scale through the NHS will matter enormously."

Longer term, Augmentive wants to measurably improve the mental wellbeing of one million people over the next decade. Norman is careful not to focus only on the topline. "We know that stress in a healthcare business doesn't show up first in financial metrics. It tends to show up in care quality metrics first, things like time to first appointment, time to receive a report, number of incidents, outcome measures. We're watching those closely, because they give us an early indicator if the service is growing too quickly."

Can you give an example or two of recent challenges you’ve had to navigate as a CEO?

In the early stages, Augmentive ran a marketplace model, connecting individuals with independent therapists. Demand was growing fast, particularly among the neurodivergent population, but Norman began to see a structural problem.

"We want to build a service you'd trust with your loved one's mental health. But we were relying on external partners to deliver key parts of the pathway and they were operating in different ways; different assessment tools, different formats, different session lengths. As we were scaling, it became very difficult to manage patient expectations or use data to improve the service."

Norman's solution was radical: Augmentive paused growth for twelve months, obtained its own CQC regulation, and rebuilt the service model from the ground up with standardised clinical governance. "You sometimes have to take one step back to take two steps forward," Norman reflects. "But when you're a startup with investors, you're analysing growth metrics weekly. Telling them we're not going to grow for twelve months requires a lot of trust, but all our investors were nothing but supportive, including our lead investor, Venrex, who've backed high growth companies such as Revolut and Maven Clinic."

Fortunately, that trust was repaid. "Once we came through that process, we grew revenue tenfold in the following nine months, nearly doubled margins, and we now have a much larger team of some of the UK's best doctors in this space."

What advice would you give to an entrepreneur going into a funding round?

Norman's first piece of advice is deceptively simple: don't oversell. "If you're having to court an investor incredibly intensively, it may be a sign that there's no natural interest in what you're building. You'll spend a huge amount of energy trying to bring them in and then they'll probably be the first to create friction when things go wrong. Best to move on and focus on where you have strong signal. Be selective."

Equally important, he argues, is for an entrepreneur to take the time to make sure the fit is genuinely right. "Vision is the easy bit, but you need alignment on outcomes too. If they're looking for a ten-billion-pound exit in seven years and that's not your market, you're just cramming your business into an investment case that just doesn't fit. If you're early-stage and raising from VCs, fund size tells you a lot. Being honest about your sector matters as well: in some spaces, health tech included, it works better to find investors whose thesis is built around both impact and a slightly longer timeline. Far better to build your plan around what you actually believe is going to happen, not around what you think an investor wants to hear."

Beyond investor selection, Norman is just as vocal about the mechanics of the deal itself. "When you're raising, it's tempting to think of equity as the only thing you're giving up. But you can also be building future problems into the cap table and the constitutional documents: complex share classes, terms that look fine at the time and come back to bite you later. It's easy to just want to get the money in so you can keep scaling, but pushing back on the structural side and being really disciplined about the basics makes life so much easier along the journey."

None of this is new advice, and Norman is the first to say so. "The basics are obvious in theory. But in practice, when you're a founder and you need capital, it's tempting to compromise. That's where I’ve personally seen a lot of founders come unstuck."

How has having Cambridge Angels in your investor group assisted you?

Augmentive has Cambridge Angels investors John Snyder and John Yeomans on its cap table and Norman is unreserved about its positive impact.

"There's real credibility in being a Cambridge Angels portfolio company. People know it's smart capital; investors with deep industry expertise, operating experience, and a track record of commercialising from an early stage."

Beyond the signal, it's the substance of engagement Norman values most. "I've always loved audiobooks; I'll go on a long walk just to listen to a founder talk about their story. Equally getting to spend time with the two Johns and hearing about their experiences, how they'd approach different challenges, has been so enjoyable and invaluable."

What has stood out is how the Johns approach problems. "They can come at them from a founder's perspective, and that's been particularly clear around fundraising: practical advice on cap table structure, who to bring in, what to look for in terms, and a much sharper sense of how the decisions you make now can make life significantly easier or harder down the line."

The Cambridge Angels events have also delivered. "There's no peacocking. You're not in a room full of people wanting to be seen as investors or builders. Everyone's just focused on what people are actually building or backing. The conversations are well-facilitated, you get introduced to the right people, and you actually come away having learned something. We've also built some really valuable relationships through it, including a particularly strong banking partner."